Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objectives of this study is to assess the safety and tolerability of
intravenously (i.v.) administered 186 Rhenium-isotope (186Re)-labelled bivatuzumab and to
investigate the biodistribution and pharmacokinetics of 186 Re-labelled bivatuzumab in
patients with non-small cell lung cancer (NSCLC)